Literature DB >> 32251150

Comparison of fresh frozen plasma vs. coagulation factor concentrates for reconstitution of blood: An in vitro study.

Johannes Gratz1, Martin Ponschab, Giacomo E Iapichino, Christoph J Schlimp, Janne Cadamuro, Oliver Grottke, Johannes Zipperle, Daniel Oberladstätter, Christian Gabriel, Bernhard Ziegler, Herbert Schöchl.   

Abstract

BACKGROUND: Many trauma centres have adopted the administration of fixed ratios of packed red blood cells (PRBCs), platelet concentrates and fresh frozen plasma (FFP) for bleeding patients. However, the haemostatic efficacy of this concept is not well proven.
OBJECTIVE: Our objective was to characterise the haemostatic profile of different ratios (2 : 1 : 1, 1 : 1 : 1 and 1 : 1 : 2) of PRBCs, platelet concentrates and FFP in comparison with coagulation factor concentrates (fibrinogen and/or prothrombin complex concentrate).
DESIGN: An in vitro study.
SETTING: Research laboratories of the department of transfusion medicine, Linz, Austria. MATERIALS: Whole blood donations from a total of 20 male volunteers. INTERVENTION: Reconstitution of blood at different ratios of PRBCs, platelet concentrates and FFP or coagulation factor concentrates. MAIN OUTCOME MEASURES: Cell count, conventional and thromboelastometric coagulation parameters, single coagulation factor activities as well as endogenous thrombin potential.
RESULTS: Fibrinogen levels and haematocrit were lower in the FFP group at any ratio compared with the concentrate-based groups (P < 0.0001). Reconstitution of blood with FFP at different ratios resulted in haematocrit or fibrinogen levels that were borderline with regard to recommended substitution triggers (haematocrit 41 ± 2% and fibrinogen 1.5 ± 0.3 g l at the 2 : 1 : 1 ratio vs. 21 ± 1% and 2.1 ± 0.4 g l respectively at the 1 : 1 : 2 ratio). Compared with FFP at any ratio, maximum clot firmness showed higher values in the groups using fibrinogen concentrate (P < 0.0001), whereas endogenous thrombin potential revealed higher values in the groups using prothrombin complex concentrate (P < 0.0001).
CONCLUSION: Use of coagulation factor concentrates for the reconstitution of blood allows for delivery of a higher haematocrit and a higher fibrinogen content compared with FFP. However, prothrombin complex concentrate might result in an unnecessary excess of thrombin generation. Clinical studies are warranted to further investigate these in vitro findings.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32251150     DOI: 10.1097/EJA.0000000000001202

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  6 in total

1.  In Reply - Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.

Authors:  Allan M Klompas; Stephen A Klassen; Jonathon W Senefeld; Michael J Joyner; Patrick W Johnson; Rickey E Carter; Camille M Van Buskirk; Jeffrey L Winters; James R Stubbs
Journal:  Mayo Clin Proc       Date:  2020-11-03       Impact factor: 7.616

2.  Sufficient Thrombin Generation Despite 95% Hemodilution: An In Vitro Experimental Study.

Authors:  Johannes Gratz; Christoph J Schlimp; Markus Honickel; Nadine Hochhausen; Herbert Schöchl; Oliver Grottke
Journal:  J Clin Med       Date:  2020-11-25       Impact factor: 4.241

3.  Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry.

Authors:  Tobias Koller; Nadia Kinast; Andres Guilarte Castellanos; Sergio Perez Garcia; Pilar Paniagua Iglesias; Xavi León Vintro; Jose Mateo Arranz; Noelia Vilalta Seto; Ma Victòria Moral García; Ana Belén Moreno-Castaño; Jose Aznar-Salatti; Gines Escolar Albaladejo; Maribel Diaz-Ricart
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2021-04-09       Impact factor: 2.953

4.  Coagulation profile of human COVID-19 convalescent plasma.

Authors:  Allan M Klompas; Noud van Helmond; Justin E Juskewitch; Rajiv K Pruthi; Matthew A Sexton; Juan C Diaz Soto; Stephen A Klassen; Katherine A Senese; Camille M van Buskirk; Jeffrey L Winters; James R Stubbs; Scott A Hammel; Michael J Joyner; Jonathon W Senefeld
Journal:  Sci Rep       Date:  2022-01-12       Impact factor: 4.379

5.  Personalized modulation of coagulation factors using a thrombin dynamics model to treat trauma-induced coagulopathy.

Authors:  Damon E Ghetmiri; Mitchell J Cohen; Amor A Menezes
Journal:  NPJ Syst Biol Appl       Date:  2021-12-07

6.  Four-factor prothrombin complex concentrate to reduce allogenic blood product transfusion in patients with major trauma, the PROCOAG trial: study protocol for a randomized multicenter double-blind superiority study.

Authors:  Pierre Bouzat; Jean-Luc Bosson; Jean-Stéphane David; Bruno Riou; Jacques Duranteau; Jean-François Payen
Journal:  Trials       Date:  2021-09-16       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.